Dentsu GAAP EPS of ¥177.58, revenue of ¥717.35B; reaffirms FY 2026 outlook
Dentsu press release (DNTUF): 1H GAAP EPS of ¥177.58. Revenue of ¥717.35B (+4.9% Y/Y).
YayaNews contributes financial news and market context through the YayaNews editorial workflow.
Dentsu press release (DNTUF): 1H GAAP EPS of ¥177.58. Revenue of ¥717.35B (+4.9% Y/Y).
Dentsu GAAP EPS of ¥177.58, revenue of ¥717.35B; reaffirms FY 2026 outlook | Seeking Alpha
Dentsu
press release
(
DNTUF
): 1H GAAP EPS of ¥177.58.
Revenue of Â¥717.35B (+4.9% Y/Y).Â
More on Dentsu
Dentsu Group Inc. (DNTUY) Q1 2026 Earnings Call Transcript
Historical earnings data for Dentsu
Financial information for Dentsu
To ensure this doesnât happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please
report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.
Search field
Entering text into the input field will update the search result below
Recommended For You
More
Trending News
See More
»
Original YayaNews editorial coverage, published for informational purposes.
This article is sourced from Seeking Alpha. It is for informational purposes only and does not constitute investment advice.
Topics & Symbols
Continue Reading
Related Reading
ING to redeem $1.75B of callable senior notes (ING:NYSE)
ING to redeem $1.75B in callable senior notes on Sept. 11, 2026 at par, including floating and fixed-to-float debt due 2027.
XBP Global targets $65M-$75M in annualized efficiencies while revenue per employee approaches $100,000 by year-end (NASDAQ:XBP)
XBP Global Q2 2026 earnings call: normalized EBITDA $21.9M, adjusted gross margin 24.9%, efficiency target raised, H2 revenue inflectionâread now.
Uber and Pony.ai to Launch 2,000 Robotaxis in Europe, Expanding Autonomous Ride-Hailing
Uber and Chinese autonomous driving firm Pony.ai plan to deploy 2,000 robotaxis in Europe, marking a strategic expansion of autonomous ride-hailing. This article analyzes the partnership's background, market challenges, and strategic implications for both companies.
Celcuity Targets Q3 2026 for REVTORPYK Launch and sNDA Submission, Accelerating Commercialization
Celcuity plans to ship REVTORPYK and file its sNDA by Q3 2026, backed by positive clinical data and commercial readiness. The market watches its execution as it transitions from clinical to commercial stage.
